Literature DB >> 22967697

Antibiotic resistance in isolates recovered from women with community-acquired urinary tract infections presenting to a tertiary care emergency department.

Lyne Filiatrault1, Rachel M McKay, David M Patrick, Diane L Roscoe, Grahame Quan, Jeff Brubacher, Ken M Collins.   

Abstract

INTRODUCTION: We sought to determine the antibiotic susceptibility of organisms causing community-acquired urinary tract infections (UTIs) in adult females attending an urban emergency department (ED) and to identify risk factors for antibiotic resistance.
METHODS: We reviewed the ED charts of all nonpregnant, nonlactating adult females with positive urine cultures for 2008 and recorded demographics, diagnosis, complicating factors, organism susceptibility, and risk factors for antibiotic resistance. Odds ratios (ORs) and 95% confidence intervals (CIs) for potential risk factors were calculated.
RESULTS: Our final sample comprised 327 UTIs: 218 were cystitis, of which 22 were complicated cases and 109 were pyelonephritis, including 22 complicated cases. Escherichia coli accounted for 82.3% of all UTIs, whereas Staphylococcus saprophyticus accounted for 5.2%. In uncomplicated cystitis, 9.5% of all isolates were resistant to ciprofloxacin and 24.0% to trimethoprim-sulfamethoxazole (TMP-SMX). In uncomplicated pyelonephritis, 19.5% of isolates were resistant to ciprofloxacin and 36.8% to TMP-SMX. In UTI (all types combined), any antibiotic use within the previous 3 months was a significant risk factor for resistance to both ciprofloxacin (OR 3.34, 95% CI 1.16-9.62) and TMP-SMX (OR 4.02, 95% CI 1.48-10.92). Being 65 years of age or older and having had a history of UTI in the previous year were risk factors only for ciprofloxacin resistance.
CONCLUSIONS: E. coli was the predominant urinary pathogen in this series. Resistance to ciprofloxacin and TMP-SMX was high, highlighting the importance of relevant, local antibiograms. Any recent antibiotic use was a risk factor for both ciprofloxacin and TMP-SMX resistance in UTI. Our findings should be confirmed with a larger prospective study.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22967697     DOI: 10.2310/8000.2012.120666

Source DB:  PubMed          Journal:  CJEM        ISSN: 1481-8035            Impact factor:   2.410


  6 in total

1.  Diagnostically challenging cases: what are atypia and dysplasia?

Authors:  Joseph Sanfrancesco; J Stephen Jones; Donna E Hansel
Journal:  Urol Clin North Am       Date:  2013-02-26       Impact factor: 2.241

2.  Escherichia coli antibiotic resistance in emergency departments. Do local resistance rates matter?

Authors:  O Grignon; E Montassier; S Corvec; D Lepelletier; J-B Hardouin; J Caillon; E Batard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-10-23       Impact factor: 3.267

Review 3.  Prevalence of antibiotic susceptibility and resistance of Escherichia coli in acute uncomplicated cystitis in Korea: Systematic review and meta-analysis.

Authors:  Jae Heon Kim; Hwa Yeon Sun; Tae Hyong Kim; Sung Ryul Shim; Seung Whan Doo; Won Jae Yang; Eun Jung Lee; Yun Seob Song
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

4.  From Pathophysiological Hypotheses to Case-Control Study Design: Resistance from Antibiotic Exposure in Community-Onset Infections.

Authors:  Salam Abbara; Didier Guillemot; Christian Brun-Buisson; Laurence Watier
Journal:  Antibiotics (Basel)       Date:  2022-02-04

5.  Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department.

Authors:  Sebastian Bischoff; Thomas Walter; Marlis Gerigk; Matthias Ebert; Roger Vogelmann
Journal:  BMC Infect Dis       Date:  2018-01-26       Impact factor: 3.090

6.  Escherichia coli Resistance to Fluoroquinolones in Community-Acquired Uncomplicated Urinary Tract Infection in Women: a Systematic Review.

Authors:  Ann E Stapleton; Florian M E Wagenlehner; Aruni Mulgirigama; Monique Twynholm
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.